← All trials
NCT06003166
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2024
- Primary completion
- Dec 31, 2027
- Completion date
- Jul 31, 2028
- First posted
- Aug 21, 2023
- Last posted
- Dec 6, 2023
- Enrollment
- 68
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of ArizonaLead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- University of ArizonaOverall official - principal investigator
- University of ArizonaReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.